Zacks Investment Research Upgrades Immunomedics, Inc. (IMMU) to Buy

Zacks Investment Research Upgrades Immunomedics, Inc. (IMMU) to Buy


The firm currently has a $3.00 price target on the biopharmaceutical company's stock. Zacks Investment Research 's price target points to a potential upside of 12.78% from the company's previous close.



from Biotech News